Inflammatory Bowel Disease

Share on facebook
Share on pinterest
Share on twitter
Share on email
Share on whatsapp

Medical cannabis for inflammatory bowel disease: real-life experience of mode of consumption and assessment of side-effects.
Eur J Gastroenterol Hepatol 2019

Timna Naftali 1 2, Lihi Bar-Lev Schleider 3, Fabiana Sklerovsky Benjaminov 1 2, Ido Lish 1 2, Fred M Konikoff 1 2, Yehuda Ringel 1 2

1Meir Medical Center Institute of Gastroenterology and Hepatology, Kfar Saba; 2Sackler School of Medicine, Tel Aviv University, Tel Aviv; 3Soroka University Medical Centre and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beersheba, Israel.

An extensive observational, real-life study with 127 IBD patients who were followed at Meir Medical Center from 2011 through 2016. Most patients reported significant improvement in their symptoms and the use of other medications after 1 year of cannabis consumption was significantly reduced.

STUDY POPULATION: 127 IBD patients who received a license for use of medical cannabis

STRAIN: Half of the patients in the study received the company’s products regularly

RESULTS:  

The average dose used was 31 ± 15 g/month. The average Harvey-Bradshaw index improved from 14 ± 6.7 to 7 ± 4.7 (P < 0.001) during a median follow-up of 44 months (interquartile range, 24-56 months). There was a slight, but statistically significant, average weight gain of 2 kg within 1 year of cannabis use. The need for other medications was significantly reduced. Employment among patients increased from 65 to 74% (P < 0.05). We conclude that the majority of inflammatory bowel disease patients using cannabis are satisfied with a dose of 30 g/month. We did not observe negative effects of cannabis use on the patients’ social or occupational status.

FULL STUDY

Have you liked our facebook page?

Common Questions

Search by Keyword

Recent publications

Ordering Tikun Olam Products

Proudly leading the revolution for modern Cannabis treatment

Related Topics

Cannabis is often used by patients with ulcerative colitis, but controlled studies are few. We aimed to assess the effect of cannabis in improving clinical and inflammatory outcomes in ulcerative colitis patients.

Brief Report: Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems—A Retrospective Feasibility StudyJ Autism Dev Disord, 2018 Adi Aran1 · Hanoch

Avidekel Cannabis extracts and cannabidiol are as efficient as Copaxone in suppressing EAE in SJL/J mice Inflammopharmacology 2018 Ruth Gallily1, Zhannah Yekhtin1 1The Lautenberg Center

Treatment of Crohn’s Disease with Cannabis: An Observational StudyIMAJ – The Israel Medical Association Journal, 2011 Timna Naftali 1, Lihi Bar Lev, Doron Yablecovitch, Elisabeth